Healthcare Industry News: IDEV Technologies
News Release - May 3, 2006
IDev Technologies, Inc. Gains CE Mark Approval for New Nitinol Stent in Peripheral Vascular DiseaseHOUSTON, May 3 (HSMN NewsFeed) -- IDEV Technologies, Inc., an emerging leader in the development and marketing of minimally invasive stent systems for the treatment of peripheral vascular and non-vascular diseases, today announces CE Mark approval for use of its stent in Europe.
Thomas M. Tully, Chairman and CEO commented, "European approval for the IDEV Technologies, Inc. stent is the first critical step toward the commercialization of this novel technology worldwide. The company is initially preparing a limited distribution strategy to elite interventional centers throughout Europe. These elite centers will be the first to offer the innovative IDEV Technologies, Inc. stent to over 2.5 million patients who suffer from Critical Limb Ischemia in the developed world."
About IDEV Technologies, Inc.
IDEV Technologies, Inc. ("IDEV") is an Innovator and Developer of next generation minimally invasive medical devices for the treatment of peripheral vascular disease (PVD). PVD is currently treated by interventional radiologists, vascular surgeons, and cardiologists. The Company has recently received a CE Mark approval for use of the stent in peripheral vascular and non-vascular applications and is preparing to launch the product in Europe shortly. The IDEV Technologies, Inc. stent is a unique device that is a self- expandable nitinol stent with significant radial force that is resistant to kinking, crushing and fracture potential. Additionally, the unique delivery system allows for precise placement and repositionability prior to deployment. These features represent a significant advance over existing stent technologies for peripheral vascular applications.
Source: IDev Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.